What is Stmm?
Stämm is at the forefront of biomanufacturing innovation, specializing in advanced solutions for biologics and cell therapies. The company leverages continuous bioprocessing and AI-driven technologies to automate production, offering end-to-end support from cell line development to multi-omic data analysis. Stämm's strategic focus on interdisciplinary collaboration and continuous learning aims to redefine biomanufacturing for clients in the research and clinical sectors, driving impactful advancements through nature-inspired approaches.
How much funding has Stmm raised?
Stmm has raised a total of $17M across 1 funding round:
Series A
$17M
Series A (2022): $17M with participation from New Abundance, Serenity Traders, Decarbonization Consortium, Vista, Trillian, Teramips, and Varana
Key Investors in Stmm
Teramips
Teramips Technologies Ltd. specializes in software development, engineering solutions, research, and a variety of consulting services, including early-stage investments in technology startups. They focus on delivering high-quality software and management consulting.
Varana
Varana specializes in sustainable luxury fashion, offering handcrafted designer clothing and accessories with a commitment to true sustainability and social conscience. Their clients seek ethically-made, high-quality fashion.
What's next for Stmm?
The recent major strategic investment signifies a pivotal moment for Stämm, positioning it for accelerated scaling and further technological development. This capital infusion is expected to bolster its capabilities in AI-driven bioprocessing and expand its market reach within the biologics and cell therapy industries. Stämm's commitment to innovation and automation suggests a strategic push towards solidifying its leadership in the biomanufacturing landscape, potentially exploring new therapeutic applications and enhancing its service offerings to meet evolving clinical demands.
See full Stmm company page
